Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ultragenyx Pharmaceutical (RARE) Total Liabilities (2016 - 2025)

Ultragenyx Pharmaceutical has reported Total Liabilities over the past 11 years, most recently at $1.6 billion for Q4 2025.

  • Quarterly Total Liabilities rose 29.33% to $1.6 billion in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $1.6 billion through Dec 2025, up 29.33% year-over-year, with the annual reading at $1.6 billion for FY2025, 29.33% up from the prior year.
  • Total Liabilities was $1.6 billion for Q4 2025 at Ultragenyx Pharmaceutical, up from $1.2 billion in the prior quarter.
  • Over five years, Total Liabilities peaked at $1.6 billion in Q4 2025 and troughed at $540.3 million in Q2 2021.
  • The 5-year median for Total Liabilities is $1.2 billion (2023), against an average of $1.0 billion.
  • The largest YoY upside for Total Liabilities was 177.67% in 2021 against a maximum downside of 12.95% in 2021.
  • A 5-year view of Total Liabilities shows it stood at $599.8 million in 2021, then surged by 98.88% to $1.2 billion in 2022, then rose by 1.9% to $1.2 billion in 2023, then rose by 2.09% to $1.2 billion in 2024, then increased by 29.33% to $1.6 billion in 2025.
  • Per Business Quant, the three most recent readings for RARE's Total Liabilities are $1.6 billion (Q4 2025), $1.2 billion (Q3 2025), and $1.1 billion (Q2 2025).